143 related articles for article (PubMed ID: 30105844)
1. A multimodality work-up of patients with Hypereosinophilia.
Hu Z; Boddu PC; Loghavi S; Miranda RN; Goswami M; Medeiros LJ; Tam W; Orazi A; Verstovsek S; Wang SA
Am J Hematol; 2018 Nov; 93(11):1337-1346. PubMed ID: 30105844
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.
Wang SA; Hasserjian RP; Tam W; Tsai AG; Geyer JT; George TI; Foucar K; Rogers HJ; Hsi ED; Rea BA; Bagg A; Bueso-Ramos CE; Arber DA; Verstovsek S; Orazi A
Haematologica; 2017 Aug; 102(8):1352-1360. PubMed ID: 28495918
[TBL] [Abstract][Full Text] [Related]
4. The Diagnostic Work-Up of Hypereosinophilia.
Wang SA
Pathobiology; 2019; 86(1):39-52. PubMed ID: 29961056
[TBL] [Abstract][Full Text] [Related]
5. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
[TBL] [Abstract][Full Text] [Related]
6. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract][Full Text] [Related]
7. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
8. Causes of hypereosinophilia in 100 consecutive patients.
Moller D; Tan J; Gauiran DTV; Medvedev N; Hudoba M; Carruthers MN; Dehghan N; van den Berghe J; Bruyère H; Chen LYC
Eur J Haematol; 2020 Sep; 105(3):292-301. PubMed ID: 32364630
[TBL] [Abstract][Full Text] [Related]
9. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.
Wang SA; Tam W; Tsai AG; Arber DA; Hasserjian RP; Geyer JT; George TI; Czuchlewski DR; Foucar K; Rogers HJ; Hsi ED; Bryan Rea B; Bagg A; Dal Cin P; Zhao C; Kelley TW; Verstovsek S; Bueso-Ramos C; Orazi A
Mod Pathol; 2016 Aug; 29(8):854-64. PubMed ID: 27174585
[TBL] [Abstract][Full Text] [Related]
11. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
12. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
14. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
15. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilic myeloid neoplasms.
Noel P; Mesa RA
Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
[TBL] [Abstract][Full Text] [Related]
17. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
[TBL] [Abstract][Full Text] [Related]
18. Hypereosinophilic Syndrome.
Curtis C; Ogbogu P
Clin Rev Allergy Immunol; 2016 Apr; 50(2):240-51. PubMed ID: 26475367
[TBL] [Abstract][Full Text] [Related]
19. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
Lierman E; Cools J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.
Schwaab J; Jawhar M; Naumann N; Schmitt-Graeff A; Fabarius A; Horny HP; Cross NC; Hofmann WK; Reiter A; Metzgeroth G
Ann Hematol; 2016 Mar; 95(4):557-62. PubMed ID: 26797429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
